WallStreetZenWallStreetZen

NASDAQ: LMAT
Lemaitre Vascular Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for LMAT

Based on 5 analysts offering 12 month price targets for Lemaitre Vascular Inc

Min Forecast
$93.00+2.49%
Avg Forecast
$100.20+10.43%
Max Forecast
$110.00+21.23%

Should I buy or sell LMAT stock?

Based on 5 analysts offering ratings for Lemaitre Vascular Inc.

Buy
Strong Buy
2 analysts 40%
Buy
2 analysts 40%
Hold
1 analysts 20%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although LMAT's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates LMAT as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their LMAT stock forecasts and price targets.

LMAT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-02-28
lockedlocked$00.00+00.00%2025-02-28
lockedlocked$00.00+00.00%2025-02-13
lockedlocked$00.00+00.00%2024-11-01
lockedlocked$00.00+00.00%2024-11-01

1 of 1

Forecast return on equity

Is LMAT forecast to generate an efficient return?

Company
18.38%
Industry
17.57%
Market
61.57%
LMAT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is LMAT forecast to generate an efficient return on assets?

Company
11.23%
Industry
12.51%
LMAT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

LMAT earnings per share forecast

What is LMAT's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$2.25+14.63%
Avg 2 year Forecast
$2.50+27.35%
Avg 3 year Forecast
$2.75+40.18%
LMAT's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

LMAT revenue forecast

What is LMAT's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$240.4M+9.35%
Avg 2 year Forecast
$261.9M+19.1%
Avg 3 year Forecast
$284.7M+29.51%
LMAT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

LMAT earnings growth forecast

How is LMAT forecast to perform vs Medical Instruments & Supplies companies and vs the US market?

Company
12.86%
Industry
20.64%
Market
22.32%
LMAT's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
LMAT's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
LMAT's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

LMAT revenue growth forecast

How is LMAT forecast to perform vs Medical Instruments & Supplies companies and vs the US market?

Company
9.23%
Industry
8.64%
Market
10.43%
LMAT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
LMAT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

LMAT vs Medical Stocks

TickerPricePrice TargetUp/downsideConsensus
LMAT$90.74$100.20+10.43%Buy
WRBY$16.51$23.36+41.47%Buy
ATRC$29.91$50.38+68.42%Strong Buy
XRAY$13.90$20.60+48.20%Buy
NVST$16.08$20.25+25.93%Hold
View Top Medical Stocks

Lemaitre Vascular Stock Forecast FAQ

Is Lemaitre Vascular Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: LMAT) stock is to Buy LMAT stock.

Out of 5 analysts, 2 (40%) are recommending LMAT as a Strong Buy, 2 (40%) are recommending LMAT as a Buy, 1 (20%) are recommending LMAT as a Hold, 0 (0%) are recommending LMAT as a Sell, and 0 (0%) are recommending LMAT as a Strong Sell.

If you're new to stock investing, here's how to buy Lemaitre Vascular stock.

What is LMAT's earnings growth forecast for 2025-2027?

(NASDAQ: LMAT) Lemaitre Vascular's forecast annual earnings growth rate of 12.86% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast earnings growth rate of 20.64%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 22.32%.

Lemaitre Vascular's earnings in 2025 is $44,038,000.On average, 6 Wall Street analysts forecast LMAT's earnings for 2025 to be $50,682,476, with the lowest LMAT earnings forecast at $50,080,161, and the highest LMAT earnings forecast at $51,884,851. On average, 5 Wall Street analysts forecast LMAT's earnings for 2026 to be $56,306,343, with the lowest LMAT earnings forecast at $54,591,887, and the highest LMAT earnings forecast at $59,103,613.

In 2027, LMAT is forecast to generate $61,979,839 in earnings, with the lowest earnings forecast at $58,652,441 and the highest earnings forecast at $66,322,375.

What is LMAT's revenue growth forecast for 2025-2027?

(NASDAQ: LMAT) Lemaitre Vascular's forecast annual revenue growth rate of 9.23% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 8.64%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.43%.

Lemaitre Vascular's revenue in 2025 is $219,863,000.On average, 5 Wall Street analysts forecast LMAT's revenue for 2025 to be $5,423,410,713, with the lowest LMAT revenue forecast at $5,391,512,809, and the highest LMAT revenue forecast at $5,506,336,241. On average, 5 Wall Street analysts forecast LMAT's revenue for 2026 to be $5,907,248,231, with the lowest LMAT revenue forecast at $5,741,171,590, and the highest LMAT revenue forecast at $6,114,742,519.

In 2027, LMAT is forecast to generate $6,423,457,384 in revenue, with the lowest revenue forecast at $6,086,318,644 and the highest revenue forecast at $6,746,384,187.

What is LMAT's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: LMAT) forecast ROA is 11.23%, which is lower than the forecast US Medical Instruments & Supplies industry average of 12.51%.

What is LMAT's Price Target?

According to 5 Wall Street analysts that have issued a 1 year LMAT price target, the average LMAT price target is $100.20, with the highest LMAT stock price forecast at $110.00 and the lowest LMAT stock price forecast at $93.00.

On average, Wall Street analysts predict that Lemaitre Vascular's share price could reach $100.20 by Feb 28, 2026. The average Lemaitre Vascular stock price prediction forecasts a potential upside of 10.43% from the current LMAT share price of $90.74.

What is LMAT's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: LMAT) Lemaitre Vascular's current Earnings Per Share (EPS) is $1.96. On average, analysts forecast that LMAT's EPS will be $2.25 for 2025, with the lowest EPS forecast at $2.22, and the highest EPS forecast at $2.30. On average, analysts forecast that LMAT's EPS will be $2.50 for 2026, with the lowest EPS forecast at $2.42, and the highest EPS forecast at $2.62. In 2027, LMAT's EPS is forecast to hit $2.75 (min: $2.60, max: $2.94).

What is LMAT's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: LMAT) forecast ROE is 18.38%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.